News
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
PORTLAND, Maine, Jan. 09, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
PORTLAND, Maine, Nov. 21, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022
Conference Call Scheduled for Tuesday, November 22, 2022 at 9:00 AM ETPORTLAND, Maine, Nov. 10, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and...
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
PORTLAND, Maine, Aug. 11, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ETPORTLAND, Maine, Aug. 04, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and...
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
PORTLAND, Maine, July 27, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
PORTLAND, Maine, July 07, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 19, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
Q1 2022 Product Sales Increased 46% over Q1 2021PORTLAND, Maine, May 12, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products...